Perspectum Partners with UT Southwestern Medical Center on Dallas Heart & Minds Study

Perspectum has announced a collaboration with UT Southwestern Medical Center, to include LiverMultiScan® technology in the Dallas Heart & Minds Study (DHMS).

Perspectum reports the DHMS initial aim was to improve the diagnosis, prevention and treatment of heart disease, over the years this has expanded to encompass metabolic diseases, such as fatty liver disease.

LiverMultiScan’s quantitative MRI technology will be used to measure chronic liver disease, enabling a deeper understanding of the interactions between genetics, environment and lifestyle on the health of the liver.

LiverMultiScan is currently being used across Dallas, and the US, to enable physicians to better diagnose and treat patients with disorders such as Fatty Liver Disease. Using a non-invasive MRI, the test gives metrics of liver tissue health that correlate with inflammation, fibrosis, fat, and iron.

“We are really excited to work with Perspectum on the Dallas Hearts and Minds Study, formerly known as Dallas Heart Study. In the previous examinations, we extensively characterized obesity and cardiometabolic risk factors in our cohort – we are about to gain critical knowledge of how long-standing obesity and metabolic syndrome can affect liver health using LiverMultiScan by Perspectum.” Dr. Jaret Berry, Principal Investigator, Dallas Heart and Minds Study

“As part of our efforts to improve the care of patients, we are using LiverMultiScan to assess the liver in this large DHMS cohort hoping to further our understanding of obesity phenotyping in the liver.” – Dr. Carlos Duncker, Medical Science Liaison, Perspectum.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”